Cargando…
Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
Doxorubicin (DXR) has a positive inoculum effect and penetrates poorly into the core of multicellular tumour spheroids (MTS). Cis-platin (DDP) displays neither of these characteristics. We evaluated whether combining these 2 agents would influence the cell kill effect at a tumour mass level. MTS wer...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246593/ https://www.ncbi.nlm.nih.gov/pubmed/3179185 |
_version_ | 1782150804430389248 |
---|---|
author | Kohno, N. Ohnuma, T. Kaneko, M. Holland, J. F. |
author_facet | Kohno, N. Ohnuma, T. Kaneko, M. Holland, J. F. |
author_sort | Kohno, N. |
collection | PubMed |
description | Doxorubicin (DXR) has a positive inoculum effect and penetrates poorly into the core of multicellular tumour spheroids (MTS). Cis-platin (DDP) displays neither of these characteristics. We evaluated whether combining these 2 agents would influence the cell kill effect at a tumour mass level. MTS were produced from a PC-10 squamous lung carcinoma cell line. MTS were exposed to either drug first for 1 h with different intervals between exposure. Cells were then trypsinized to a single cell suspension and subjected to clonogenic assay. Combination effects were analyzed by median effect plot analysis. The more MTS ml-1 medium, the lower the cell kill effect of DXR. Simultaneous exposure to the 2 drugs was synergistic. DXR exposure first followed by DDP was less efficacious than, or the same as, the simultaneous exposure. In contrast, DDP followed by DXR was more efficacious with the best cell kill at a 1 h interval between each drug. This phenomenon was observed even at non-toxic doses of DDP. The fluorescent microscopic study of DXR indicated that prior exposure of MTS to DDP resulted in increased DXR penetration into the MTS core leading to heightened synergism with this sequence. These data suggest that the proper combination of DXR plus DDP should be in sequence with DDP first. Clinical, toxicological and pharmacological trials of DDP administration first, followed by DXR, are warranted. IMAGES: |
format | Text |
id | pubmed-2246593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1988 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22465932009-09-10 Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. Kohno, N. Ohnuma, T. Kaneko, M. Holland, J. F. Br J Cancer Research Article Doxorubicin (DXR) has a positive inoculum effect and penetrates poorly into the core of multicellular tumour spheroids (MTS). Cis-platin (DDP) displays neither of these characteristics. We evaluated whether combining these 2 agents would influence the cell kill effect at a tumour mass level. MTS were produced from a PC-10 squamous lung carcinoma cell line. MTS were exposed to either drug first for 1 h with different intervals between exposure. Cells were then trypsinized to a single cell suspension and subjected to clonogenic assay. Combination effects were analyzed by median effect plot analysis. The more MTS ml-1 medium, the lower the cell kill effect of DXR. Simultaneous exposure to the 2 drugs was synergistic. DXR exposure first followed by DDP was less efficacious than, or the same as, the simultaneous exposure. In contrast, DDP followed by DXR was more efficacious with the best cell kill at a 1 h interval between each drug. This phenomenon was observed even at non-toxic doses of DDP. The fluorescent microscopic study of DXR indicated that prior exposure of MTS to DDP resulted in increased DXR penetration into the MTS core leading to heightened synergism with this sequence. These data suggest that the proper combination of DXR plus DDP should be in sequence with DDP first. Clinical, toxicological and pharmacological trials of DDP administration first, followed by DXR, are warranted. IMAGES: Nature Publishing Group 1988-09 /pmc/articles/PMC2246593/ /pubmed/3179185 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Kohno, N. Ohnuma, T. Kaneko, M. Holland, J. F. Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
title | Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
title_full | Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
title_fullStr | Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
title_full_unstemmed | Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
title_short | Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
title_sort | interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246593/ https://www.ncbi.nlm.nih.gov/pubmed/3179185 |
work_keys_str_mv | AT kohnon interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture AT ohnumat interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture AT kanekom interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture AT hollandjf interactionsofdoxorubicinandcisplatininsquamouscarcinomacellsinculture |